RGD‐Modified PEG‐PAMAM‐DOX Conjugate: In Vitro and In Vivo Targeting to Both Tumor Neovascular Endothelial Cells and Tumor Cells
RGD‐Modified PEG‐PAMAM‐DOX Conjugate: In Vitro and In Vivo Targeting to Both Tumor Neovascular Endothelial Cells and Tumor Cells
复制标题
DOI：
10.1002/adma.201003944
复制
发表时间：
2011-03
影响因子：
29.4
通讯作者：
Saijie Zhu;Lili Qian;Ming-huang Hong;Lihong Zhang;Y. Pei;Yanyan Jiang
中科院分区：
文献类型：
--
作者：
Saijie Zhu;Lili Qian;Ming-huang Hong;Lihong Zhang;Y. Pei;Yanyan Jiang
将抗癌药物选择性靶向至肿瘤部位对于有效的癌症治疗是至关重要的。细胞粘附分子整合素α v β 3在静止血管中不易检测到，但在血管生成血管和肿瘤细胞中高度表达。[ 1 ]整合素α v β 3的这种受限制的表达谱和良好的可及性使其成为药物递送目的的理想靶标。[ 2 ]许多合成的环化甘氨酸-甘氨酸-天冬氨酸序列（RGDs）含有肽，如RGDyK、RGDfK、RGDfV和RGDyV，已被鉴定与整合素α v β 3具有高亲和力。人们对合成和利用聚合物-RGD缀合物用于药物递送、[ 3 ]基因递送[ 4 ]和成像应用的兴趣越来越大。[五]《中国日报》
Selective targeting of anticancer drugs to the tumor site is critical for effective cancer therapy. The cell adhesion molecule integrin α v β 3 is not readily detectable in quiescent vessels but highly expressed in angiogenic vessels and tumor cells. [ 1 ] This restricted expression profi le and good accessibility of integrin α v β 3 make it an ideal target for drug delivery purposes. [ 2 ] A number of synthetic cyclized arginine–glycine–aspartic acid sequences (RGDs) containing peptides, such as RGDyK, RGDfK, RGDfV, and RGDyV, have been identifi ed to have high affi nity with integrin α v β 3 . There has been growing interest in the synthesis and utilization of polymer–RGD conjugates for drug delivery, [ 3 ] gene delivery, [ 4 ] and imaging applications. [ 5 ]